New research indicates that individuals with psoriasis undergoing biologic therapy exhibit higher Demodex mite density and increased demodicosis prevalence compared to untreated or topically treated patients, suggesting a potential link between biologics and elevated Demodex levels due to cytokine blockade .
Study Overview:
Led by Hasan Aksoy from Istanbul Medeniyet University Prof. Dr. Suleyman Yalcin City Hospital, researchers investigated Demodex density among psoriasis patients receiving biologic treatment versus those untreated or treated topically. The study aimed to explore the impact of biologics on skin immunity by evaluating Demodex mite levels .
Methods and Data Collection:
The cross-sectional study, conducted from May to June 2023, gathered demographic data and psoriasis treatment history via standardized forms. Participants were assessed for conditions linked to increased Demodex density. Skin surface biopsy technique (SSSB) was used to evaluate Demodex density on facial regions .
Key Findings:
Researchers observed significantly higher Demodex density in patients receiving biologics, particularly on cheeks (left: 8.15/cm2; right: 7.29/cm2) compared to controls (left: 0.24/cm2; right: 0.12/cm2). Demodicosis prevalence was notably higher in the biologic group on cheeks (left: 44.1%; right: 41.2%) and foreheads (35.3%) .
Conclusion:
The study contributes to evidence linking immunosuppression and Demodex colonization, underscoring the association between biologic therapy and Demodex density in psoriasis patients. Further research is needed to explore interventions for reducing demodicosis risk in immunosuppressed individuals .
This revised article summarizes the study’s objectives, methods, and findings in a concise and professional news format, highlighting the significance of the research in understanding the relationship between biologic therapy and Demodex mite density in psoriasis patients.
